01 enero 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions. Insights From the NCDR Cath-PCI Registry

Thomas T. Tsai, MD, MSc∗; Uptal D. Patel, MD‡; Tara I. Chang, MD, MS§; Kevin F. Kennedy, MS‖; Frederick A. Masoudi, MD, MSPH∗; Michael E. Matheny, MD, MSc, MPH∗∗; Mikhail Kosiborod, MD‖; Amit P. Amin, MD, MSc‖; John C. Messenger, MD∗; John S. Rumsfeld, MD, PhD∗; John A. Spertus, MD, MPH‖

Objectives: This study sought to examine the contemporary incidence, predictors and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions.

01 enero 2014

JACC: CARDIOVASCULAR INTERVENTIONS. The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization. First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus Uncoated Balloon Angioplasty

Dierk Scheinert, MD∗; Stephan Duda, MD†; Thomas Zeller, MD‡; Hans Krankenberg, MD§; Jens Ricke, MD‖; Marc Bosiers, MD¶; Gunnar Tepe, MD#; Scott Naisbitt, MD, PhD∗∗; Kenneth Rosenfield, MD††

Objectives: This study sought to evaluate the safety and efficacy of the Lutonix drug-coated balloon (DCB) coated with 2 μg/mm2 paclitaxel and a polysorbate/sorbitol carrier for treatment of femoropopliteal lesions.

01 enero 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. A Pre-Specified Analysis From the PRODIGY Study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia study)

Marco Valgimigli, MD, PhD∗; Matteo Tebaldi, MD†; Marco Borghesi, MD†; Pascal Vranckx, MD‡; Gianluca Campo, MD†; Carlo Tumscitz, MD†; Elisa Cangiano, MD†; Monica Minarelli, MD†; Antonella Scalone, MD†; Caterina Cavazza, MD†; Jlenia Marchesini, MD†; Giovanni Parrinello, PhD§

Objectives: This study sought to assess device-specific outcomes after implantation of bare-metal stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting stents (PES), or everolimus-eluting stents (EES) (Medtronic Cardiovascular, Santa Rosa, California) in all-comer patients undergoing percutaneous coronary intervention.

01 enero 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease

Klaus Tiroch, MD∗; Julinda Mehilli, MD†; Robert A. Byrne, MB§; Stefanie Schulz, MD§; Steffen Massberg, MD†; Karl-Ludwig Laugwitz, MD‡; Marc Vorpahl, MD∗; Melchior Seyfarth, MD∗; Adnan Kastrati, MD‡

Objectives: This study sought to evaluate the impact of anatomic and procedural variables on the outcome of the unprotected left main coronary artery (uLMCA) itself after drug-eluting stent (DES) implantation.

01 agosto 2013

THE LANCET. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial

Matthias Thielmann MD , Eva Kottenberg MD , Petra Kleinbongard PhD , Daniel Wendt MD , Nilgün Gedik MSc , Susanne Pasa MD , Vivien Price , Konstantinos Tsagakis MD , Prof Markus Neuhäuser PhD , Prof Jürgen Peters MD , Prof Heinz Jakob MD , Prof Gerd Heusch FRCP Corresponding Author

Background: Remote ischaemic preconditioning has been associated with reduced risk of myocardial injury after coronary artery bypass graft (CABG) surgery. We investigated the safety and efficacy of this procedure.

01 agosto 2013

THE LANCET. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

Dr Stephen D Wiviott MD , Prof Harvey D White DS, Prof E Magnus Ohman MB , Prof Keith AA Fox MBChB , Prof Paul W Armstrong MD, Dorairaj Prabhakaran MD, Gail Hafley MS, Yuliya Lokhnygina PhD, Prof William E Boden MD , Prof Christian Hamm MD, Peter Clemmensen MD, Jose C Nicolau MD, Alberto Menozzi MD, Witold Ruzyllo MD, Petr Widimsky MD, Ali Oto MD, Jose Leiva-Pons MD, Gregory Pavlides MD, Kenneth J Winters MD, Matthew T Roe MD, Prof Deepak L Bhatt MD, MPH

Background: Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only. We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen.

01 agosto 2013

THE LANCET. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

Dr Gregg W Stone MD, Bernhard Witzenbichler MD, Giora Weis MD, Michael J Rinaldi MD, Franz-Josef Neumann MD, D Christopher Metzger MD, Timothy D Henry MD, David A Cox MD, Peter L Duffy MD, Ernest Mazzaferri MD, Paul A Gurbel MD, Ke Xu Ph, Helen Parise MS, Ajay J Kirtane MD, Bruce R Brodie MD, Roxana Mehran MD, Thomas D Stuckey MD, for the ADAPT-DES Investigators

Background: The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical outcomes after successful coronary drug-eluting stent implantation.

01 diciembre 2013

JOURNAL OF ENDOVASCULAR THERAPY. Periscope Endograft Technique to Revascularize the Left Subclavian Artery During Thoracic Endovascular Aortic Repair

Mario Lachat , MD; Dieter Mayer , MD; Thomas Pfammatter , MD; Frank J. Criado , MD; Zoran Rancic , MD, PhD; Thomas Larzon , MD, PhD; Frank J. Veith , MD; and Felice Pecoraro , MD

Purpose: To present early and midterm results of the periscope endograft (PG) technique to maintain left subclavian artery (LSA) blood flow in thoracic endovascular aortic repairs (TEVAR) involving zone 3.

01 noviembre 2012

AMERICAN HEART JOURNAL. ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

Roberto Diletti, MD , Patrick W. Serruys, MD, PhD, FESC , Vasim Farooq, MBChB, MRCP , Krishnankutty Sudhir, MD, PhD , Cecile Dorange, MSc , Karine Miquel-Hebert, PhD , Susan Veldhof, RN , Richard Rapoza, PhD , Yoshinobu Onuma, MD , Hector M. Garcia-Garcia, MD, PhD , Bernard Chevalier, MD

Background: Currently, no data are available on the direct comparison between the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) and conventional metallic drug-eluting stents.

01 noviembre 2013

CANADIAN JOURNAL OF CARDIOLOGY. Left Atrial Appendage Occlusion Study II (LAAOS II)

Richard P. Whitlock, MD, PhD , Jessica Vincent, MSc , Mary Helen Blackall, BScN , Jack Hirsh, MD , Stephen Fremes, MD , Richard Novick, MD , P.J. Devereaux, MD, PhD , Kevin Teoh, MD , Andre Lamy, MD , Stuart J. Connolly, MD , Salim Yusuf, DPhil , Michel Carrier, MD , Jeff S. Healey, MD

Background: Occlusion of the left atrial appendage (LAA) is a potential alternative to anticoagulation for patients with atrial fibrillation (AF); however, evidence of its safety and efficacy is lacking. The Left Atrial Appendage Occlusion Study II (LAAOS II) explored the feasibility of a definitive trial of LAA occlusion for stroke prevention in AF.

01 noviembre 2013

AMERICAN HEART JOURNAL. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial

Francesco Liistro, MD , Italo Porto, MD, PhD , Paolo Angioli, MD , Simone Grotti, MD , Kenneth Ducci, MD , Giovanni Falsini, MD , Leonardo Bolognese, MD

Background: Paclitaxel-eluting balloons (PEBs) are a promising alternative to drug-eluting stent (DES) in the treatment of coronary stenoses. The aim of our study was to compare the 9-month restenosis rates of a strategy of predilatation with PEB followed by bare-metal CoCr stent (PEB + BMS group) versus implantation of everolimus DES (DES group).

01 octubre 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS: Sex-Related Differences in Outcomes After Transcatheter Aortic Valve Implantation. A Systematic Review and Meta-analysis

Zhen-Gang Zhao, MD*, Yan-Biao Liao, MD*, Yong Peng, MD, Hua Chai, MD, Wei Liu, MD, Qiao Li, MD, Xin Ren, MD, Xue-Qin Wang, MS, Xiao-Lin Luo, MD, Chen Zhang, MD, Li-Hui Lu, MS, Qing-Tao Meng, MD, Chi Chen, MD, Mao Chen, MD, PhD, Yuan Feng, MD and De-Jia Huang, MD

Background—There were considerable discrepancies with regard to sex-related differences in complications and prognosis after transcatheter aortic valve implantation.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Chronic Obstructive Pulmonary Disease in Patients Undergoing Transcatheter Aortic Valve Implantation. Insights on Clinical Outcomes, Prognostic Markers, and Functional Status Changes

Michael Mok, MBBS∗; Luis Nombela-Franco, MD∗; Eric Dumont, MD∗; Marina Urena, MD∗; Robert DeLarochellière, MD∗; Daniel Doyle, MD∗; Jacques Villeneuve, MD†; Mélanie Côté, MSc∗; Henrique B. Ribeiro, MD∗; Ricardo Allende, MD∗; Jerôme Laflamme, MS∗; Hugo DeLarochellière, MS∗; Louis Laflamme, MS∗; Ignacio Amat-Santos, MD∗; Philippe Pibarot, PhD∗; François Maltais, MD‡; Josep Rodés-Cabau, MD∗

Objectives: This study sought to determine the effects of chronic obstructive pulmonary disease (COPD) on clinical outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) and to determine the factors associated with worse outcomes in COPD patients.

01 noviembre 2013

CANADIAN JOURNAL OF CARDIOLOGY. The Effect of Percutaneous Coronary Intervention of Chronically Totally Occluded Coronary Arteries on Left Ventricular Global and Regional Systolic Function

Idan Roifman, MD , Gideon A. Paul, MD , Mohammad I. Zia, MD , Lynne K. Williams , Stuart Watkins, MD , Harindra C. Wijeysundera, MD, PhD , Andrew M. Crean, MD, MSc , Bradley H. Strauss, MD, PhD , Alexander J. Dick, MD , Graham A. Wright, PhD , Kim A. Connelly, MBBS, PhD

Background: Percutaneous coronary intervention (PCI) is frequently attempted to open chronic total occlusions (CTOs) and restore epicardial coronary flow. Data suggest adverse outcomes in the case of PCI failure. We hypothesized that failure to open a CTO might adversely affect regional cardiac function and promote deleterious cardiac remodelling, and success would improve global and regional cardiac function assessed using cardiac magnetic resonance and velocity vector imaging.

01 noviembre 2013

AMERICAN HEART JOURNAL. Warfarin use among older atrial fibrillation patients with non–ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy

Emil L. Fosbol, MD, PhD , Tracy Y. Wang, MD, MHS, MSc , Shuang Li, MS , Jonathan Piccini, MD, MHS , Renato D. Lopes, MD, PhD , Roger M. Mills, MD , Winslow Klaskala, PhD, MS , Laine Thomas, PhD , Matthew T. Roe, MD, MHS , Eric D. Peterson, MD, MPH

Background: We sought to determine the risk of readmission for bleeding and major cardiac events in stented non–ST-segment elevation myocardial infarction (NSTEMI) atrial fibrillation (AF) patients.